Andor Glaudemans
prof. dr.
I am a nuclear medicine specialist and always trying to implement innovative diagnostic and therapeutic methods in imaging. My main research interests involve infectious and inflammatory diseases, tumor-immunology, and development of new-targeted diagnostic tools for PET imaging. The latter focus is carried out in close collaboration with our radiochemists. Within the lymphoma research Groningen team we have a close collaboration with the department of hematology. The research is focused on finding new methods for diagnosis and therapy evaluation in several types of lymphomas. We have a special interest in post-transplant lymphatic disorders (PTLD). Furthermore, we are developing and evaluating several fields of radionuclide therapy, so called theranostics.
Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.117.193649
document
In addition to the well-known estrogen receptor (ER) and human epidermal growth factor receptor 2, the androgen receptor (AR) is also a potential drug target in breast cancer treatment. Whole-body imaging can provide information across lesions within a patient. ER expression in tumor lesions can be visualized by F-18-fluoroestradiol (F-18-FES) PET, and AR expression has been visualized in prostate cancer patients with F-18-fluorodihydrotestosterone (F-18-FDHT) PET. Our aim was to assess the concordance between F-18-FDHT and F-18-FES PET and tumor AR and ER expression measured immunohistochemically in patients with...
Clasina M. Venema, Lemonitsa H. Mammatas, Carolina P. Schröder, Michel van Kruchten, Giulia Apollonio, Andor W. J. M. Glaudemans, Alfons H. H. Bongaerts, Otto S. Hoekstra, Henk M. W. Verheul, Epi Boven, Bert van der Vegt, Erik F. J. de Vries, Elisabeth G. E. de Vries, Ronald Boellaard, Catharina W. Menke van der Houven van Oordt, Geke A. P. Hospers
In vivo quantification of ERβ expression by pharmacokinetic modeling: Studies with 18F-FHNP PET
Published in: Journal of Nuclear Medicine
Access to document
10.2967/jnumed.117.192666
document
The estrogen receptor (ER) is a target for endocrine therapy in breast cancer patients. Individual quantification of ER alpha and ER beta expression, rather than total ER levels, might enable better prediction of the response to treatment. We recently developed the tracer 2-F-18-fluoro-6-(6-hydroxynaphthalen-2-yl) pyridin-3-ol (F-18-FHNP) for assessment of ER beta levels with PET. In the current study, we investigated several pharmacokinetic analysis methods to quantify changes in ER beta availability with F-18-FHNP PET. Methods: Male nude rats were subcutaneously inoculated in the shoulder with ER alpha/ER beta-expressing SKOV3...
Qualitative and quantitative analyses of F-18-FES and F-18-FDHT uptake in patients with metastatic breast cancer: an interobserver variability study
L. H. Mammatas, C. M. Venema, C. P. Schröder, M. van Kruchten, G. Apollonio, A. W. J. M. Glaudemans, A. H. H. Bongaerts, O. S. Hoekstra, H. M. W. Verheul, E. Boven, B. van der Vegt, E. F. J. de Vries, E. G. E. de Vries, R. Boellaard, G. A. P. Hospers, C. W. Menke-van der Houven van Oordt
A PET imaging study to investigate the biodistribution and clearance of an albumin binding domain antibody (AlbudAb (TM)) in healthy subjects
K. Thorneloe, M. Bergstrom, L. Galinanes-Garcia, P. Galette, W. Al-Azzam, V. Vincent, D. Vugts, G. van Dongen, P. Elsinga, J. Wiegers, A. Glaudemans, J. Renaux, M. Cleveland, M. Davies, S. Zhang
Quantification of 6-[F-18]fluoro-L-3,4-dihydroxyphenyl alanine Uptake in Neuroendocrine Tumour Lesions: The Effect of Specific Activity
R. S. B. H. Schreuder, A. H. Brouwers, P. H. Elsinga, R. H. J. A. Slart, A. M. E. Walenkamp, A. W. J. M. Glaudemans, G. Luurtsema